Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00326)
Name
Indacaterol
Synonyms    Click to Show/Hide the Synonyms of This API
Indacaterol; 312753-06-3; QAB-149; QAB149; Arcapta; QAB 149; Onbrez; UNII-8OR09251MQ; 753498-25-8; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; 312753-06-3 (free base); (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; (R)-5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-[(1R)-2-[(5,6-DIETHYL-2,3-DIHYDRO-1H-INDEN-2-YL)AMINO]-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE; 5-{(1R)-2-((5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; 1000160-87-1; QABI49; SCHEMBL48098; cc-308; GTPL7455; DTXSID90185198; HMS3886I14; BCP03766; ABP001015; BDBM50318159; MFCD18782702; ZINC35801098; AKOS024463516; BCP9000787; CCG-268560; CS-0744; DB05039; SB20619; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; NCGC00386216-07; AC-27668; AS-56318; HY-14299; BCP0726000140; D09318; AB01565805_02; 753I063; Q425654; J-521526; (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1h-quinolin-2-one; 8-Hydroxy-5-[(R)-1-hydroxy-2-(5,6-diethylindan-2-ylamino)-ethyl]-1H-quinolin-2-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one; 5-[(1R)-2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one; QAB 149
Clinical Status
Approved
Disease Indication Chronic obstructive pulmonary disease ICD-11: CA22 [1]
PubChem CID
6918554
Formula
C24H28N2O3
Canonical SMILES
CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
InChI
1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
InChIKey
QZZUEBNBZAPZLX-QFIPXVFZSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=6918554"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 392.5 Topological Polar Surface Area 81.6
XlogP 3.3 Complexity 589
Heavy Atom Count 29 Rotatable Bond Count 6
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Indacaterol 0.075 mg powder Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate
                   Dosage Form Inhalant Powder
                   Company Novartis Pharmaceuticals Corporation; Sunovion Pharmaceuticals
          Indacaterol Maleate eq 75mcg base powder Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose Monohydrate (Contains Trace Levels Of Milk Protein)
                   Dosage Form Powder
                   Company Novartis
References
1 FDA label for approved indacaterol from the official website of the U.S. Food and Drug Administration.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.